PDS Biotechnology Corp (PDSB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, PDS Biotechnology reported revenue of $0. Net income was -$34.5M, or -$0.74 per diluted share. Operating activities generated -$27.8M of cash. At fiscal year end, PDS Biotechnology held $30.5M in total assets against $21.2M in total liabilities, including $26.7M of cash and equivalents.
Open the full interactive PDS Biotechnology financials → Quarterly statements, key ratios, valuation history and price charts.
PDS Biotechnology Key Stats
| Share Price | $1.60 |
|---|---|
| Market Cap | $89.1M |
| 52-Week Range | $0.20 – $1.60 |
| Shares Outstanding | 55.7 million (basic, 2026 Q2) |
PDS Biotechnology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$14.9M | -$21.4M | -$41.7M | -$43.0M | -$36.3M | -$31.5M |
| Pre-Tax Income | -$14.8M | -$21.4M | -$42.1M | -$44.3M | -$38.5M | -$35.7M |
| Income Tax | $0 | -$4.5M | -$1.2M | -$1.4M | -$869,169 | -$1.2M |
| Net Income | -$14.8M | -$16.9M | -$40.9M | -$42.9M | -$37.6M | -$34.5M |
| Diluted EPS | -$0.89 | -$0.66 | -$1.43 | -$1.39 | -$1.03 | -$0.74 |
PDS Biotechnology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$9.0M | -$7.6M | -$7.3M | -$9.8M |
| Diluted EPS | -$0.19 | -$0.16 | -$0.13 | -$0.18 |
PDS Biotechnology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.8M | $65.2M | $73.8M | $56.6M | $41.7M | $26.7M |
| Current Assets | $30.3M | $66.8M | $76.5M | $59.1M | $45.1M | $28.3M |
| Total Assets | $30.9M | $67.2M | $77.0M | $59.4M | $45.4M | $30.5M |
| Current Liabilities | $3.3M | $3.8M | $9.8M | $13.6M | $17.1M | $9.5M |
| Total Long-Term Debt | — | — | $23.0M | $23.7M | $21.7M | $16.9M |
| Total Liabilities | $3.8M | $4.0M | $33.0M | $33.3M | $26.4M | $21.2M |
| Shareholders' Equity | $27.1M | $63.2M | $44.0M | $26.1M | $19.0M | $9.3M |
PDS Biotechnology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$13.1M | -$12.5M | -$25.7M | -$33.6M | -$35.0M | -$27.8M |
| Cash From Investing | $0 | — | — | — | -$29,000 | $0 |
| Cash From Financing | $29.8M | $48.9M | $34.3M | $16.4M | $20.2M | $12.8M |
| Free Cash Flow | — | — | — | — | -$35.1M | -$27.8M |
Figures from PDS Biotechnology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full PDS Biotechnology financials page for every line item.
PDS Biotechnology Company Profile
| Ticker | PDSB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Princeton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001472091 |
Frequently Asked Questions
What was PDS Biotechnology's revenue in fiscal 2025?
PDS Biotechnology (PDSB) reported revenue of $0 for fiscal 2025.
What is PDS Biotechnology's annual revenue history?
PDS Biotechnology's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was PDS Biotechnology's net income in fiscal 2025?
PDS Biotechnology reported net income of -$34.5M for fiscal 2025.
What was PDS Biotechnology's earnings per share (EPS) in fiscal 2025?
PDS Biotechnology's diluted EPS was -$0.74 for fiscal 2025 (adjusted for any later stock splits).
What was PDS Biotechnology's revenue last quarter?
In its most recent reported quarter (2026 Q2), PDS Biotechnology reported revenue of $0.
How much debt does PDS Biotechnology have?
PDS Biotechnology reported $16.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of PDS Biotechnology are outstanding?
PDS Biotechnology reported a weighted average of 55.7 million basic shares outstanding in 2026 Q2.
What is PDS Biotechnology's market cap?
Based on its latest closing price, PDS Biotechnology (PDSB) has a market capitalization of about $89.1M.
When does PDS Biotechnology's fiscal year end?
PDS Biotechnology's fiscal year end, as registered with the SEC, is December 31.
Where is PDS Biotechnology headquartered?
PDS Biotechnology lists its business address in Princeton, New Jersey in its SEC filings.